Strategic partnerships Telethon Italy actively partners with biotech and pharma players (e.g., AGC Biologics for WASKYRA development, Can-Fite, Charles River) and collaborates with TIGEM and SR-Tiget, indicating a receptive environment for joint research, contract development, and technology licensing opportunities.

Funding and grants With a long track record of investing hundreds of millions into research and supporting thousands of projects, Telethon is a potential source of co-funding, sponsored research programs, and grant-based collaborations that can de-risk joint ventures and expand pipeline opportunities.

Gene therapy focus Telethon’s emphasis on genetic diseases, gene therapy, and ex vivo approaches (plasmid DNA production for lentivirus, WAS gene therapy) suggests strong interest in vector manufacturing, plasmid supply, regulatory consulting, and translational development services that align with late-stage and translational partners.

Clinical and translational readiness Active collaboration with clinical and academic institutes, including TIGEM and AAVantgarde Bio, signals a readiness to move programs toward clinical translation, presenting opportunities for CRO/CMO services, preclinical studies, and GMP manufacturing partnerships.

Global collaboration potential Engagement with international partners and a publicly stated aim to enable gene therapies for rare diseases positions Telethon as a gateway for global research alliances, technology transfer, and cross-border funding programs that can broaden market access and accelerate product development.